Articles

CoreValve, high risk study, TAVR, Medtronic, ACC

Medtronic plc unveiled new two-year data from the CoreValve U.S. Pivotal High Risk Study, which demonstrated superior two-year survival benefits from transcatheter aortic valve replacement (TAVR)...

Edwards, Sapien, PARTNER trial, five-year outcomes, ACC

Five-year data suggest that the Sapien transcatheter heart valve (Edwards Lifesciences) is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart...

Minneapolis Heart Institute Foundation, PCI, STEMI, late presenters

New research from the Minneapolis Heart Institute Foundation (MHIF) finds that percutaneous coronary intervention for heart attacks can still be beneficial for patients who get to their more than...

Medtronic, Drug Filled Stent, clinical trial, ACC

Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed...

Boston Scientific, Watchman LAA device, FDA approval

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction...

UTHealth, telemedicine, acute stroke, telestroke

For the first time, researchers at The University of Texas Health Science Center at Houston (UTHealth) were able to enroll patients at other hospitals into an acute stroke clinical trial.

TAVR, TAVI, acc, ACC.15, corevalve

Key data from many transcatheter aortic valve replacement (TAVR) clinical trials will be presented as late-breakers at the American College of Cardiology (ACC) Scientific Session this weekend,...

VTEC, NYU Langone, venous therapies, deep vein thrombosis, DVT, PE

NYU Langone Medical Center has announced the creation of a new multidisciplinary Venous Thromboembolic Disease Center (VTEC) to treat those with life-threatening blood clots. The new...

PE, pulmonary embolism, thrombolysis, Ekos, Ekosonic

The continuity within clinical conference topics from year to year and how presentations augment one another tells us a lot about where medicine is headed. Pulmonary embolism (PE) therapies were a...